Compare Incyte Corporation (INCY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Atlassian Corporation PLC — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Atlassian Corporation PLC trades at $207 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 2.3× Incyte Corporation's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Atlassian Corporation PLC for 65 Days on average.
| INCY | TEAM | |
|---|---|---|
Market Cap | $22.85B | $51.53B |
Volume | 1,927,029 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $129.93 | $203.57 |
52-Week Low | $83.80 | $57.15 |
Typical Hold Time | 33 Days | 65 Days |
Enterprise Value | $18.35B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Atlassian (TEAM) trades at $206.79, up 5.68% with strong bullish momentum. The stock shows robust technical strength with moving averages signaling buy and price above key resistance levels. Fundamentally, revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable. Recent earnings beats and strong analyst consensus (69.77% buy ratings) support the positive sentiment, while AI-driven product adoption and cloud migration provide growth catalysts.
The outlook remains positive with AI adoption and cloud growth driving momentum, though valuation metrics appear stretched with negative profitability. Key risks include high P/S ratio (8.06), competitive pressures, and execution challenges in maintaining growth trajectory. The consensus price target of $191.16 suggests potential downside from current levels despite strong fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
